RESUMEN
OBJECTIVE: The Hereditary Haemorrhagic Telangiectasia (HHT) is a low prevalence disease which presents heterogeneous signs and symptoms and just few population-based epidemiological studies are available. The aims of this paper were to describe the sociodemographic characteristics of people affected by HHT in the Valencian Region (VR), to determine its prevalence and mortality rate, and to analyse the sources of recruitment and verification tests used by the Rare Diseases Information System of the VR (SIER-CV). METHODS: Cross-sectional observational epidemiological study of HHT prevalent cases between 2010-2019 in SIER-CV was performed. The distribution of sociodemographic and clinical characteristics were determined, the prevalence and mortality rates, and the sources of recruitment and verification tests used by SIER-CV were analysed. Statistical analysis was performed using Stata (version 16.1) and Microsoft Excel Office. RESULTS: During 2010-2019, two hundred cases were identified, 55.5% were female. The mean ages were: 56.8 years at recruitment and 50.9 years at diagnosis. 48.4% of cases were diagnosed between thirty-six/sixty-four years of age. 25.5% died, with a mean age of 76.6 years, identifying statistically significant differences above the age of 64. The prevalence was 39.6/1,000,000 inhabitants and the crude mortality rate was 10.1/1,000,000 inhabitants. 95.5% of cases were recruited from the Hospital discharges database and the most frequent verification test was the clinical basis (45.7%). CONCLUSIONS: The increasing trend in prevalence coincides with a better knowledge of HHT, which favours its detection, and also with dying at older ages. To describe the situation of HHT in the VR facilitates its health management and contributes to the establishment of the relevant health policies for the HHT. The need to promote genetic diagnosis and to incorporate the Primary Care Clinical History as a source of recruitment in the population-based registries has been shown.
OBJECTIVE: La Telangiectasia Hemorrágica Hereditaria (THH) es una enfermedad de baja prevalencia, que se presenta con signos y síntomas muy heterogéneos y de la que apenas se dispone de estudios epidemiológicos de base poblacional. Los objetivos de este estudio fueron describir las características sociodemográficas de las personas afectadas por THH en la Comunitat Valenciana (CV), determinar su prevalencia y mortalidad, y analizar las fuentes de captación y pruebas de verificación utilizadas por el Sistema de Información de Enfermedades Raras de la CV (SIER-CV). METHODS: Se realizó un estudio epidemiológico observacional transversal de casos prevalentes de THH durante 2010-2019 en el SIER-CV. Se determinó la distribución de las características sociodemográficas y clínicas, la prevalencia y mortalidad, y se analizaron las fuentes de captación y pruebas de verificación utilizadas por SIER-CV. El análisis estadístico de los datos se realizó mediante el programa Stata (versión 16.1) y Microsoft Excel Office. RESULTS: Durante 2010-2019 se identificaron doscientos casos, de los que el 55,5% eran mujeres. Las edades medias fueron: de captación 56,8 años, y de diagnóstico 50,9 años. El 48,4% fueron diagnosticados entre los treinta y seis, y los sesenta y cuatro años. Fallecieron el 25,5%, con 76,6 años de edad media, identificándose diferencias estadísticamente significativas en mayores de sesenta y cuatro años. La prevalencia fue 39,6 por cada millón de habitantes y la tasa cruda de mortalidad de 10,1 por cada millón de habitantes. El 95,5% se captaron por el Conjunto Mínimo Básico de Datos y la prueba de verificación más frecuente fue la base clínica (45,7%). CONCLUSIONS: La tendencia ascendente de la prevalencia coincide con un mejor conocimiento de la THH, que facilita la detección de casos, y también con fallecimientos en edades avanzadas. Describir la situación de la THH en la CV facilita su manejo sanitario y contribuye al establecimiento de las políticas sanitarias correspondientes. Se muestra la necesidad de favorecer el diagnóstico genético e incorporar la Historia de Atención Primaria como fuente de captación en los registros poblacionales.
Asunto(s)
Telangiectasia Hemorrágica Hereditaria , Humanos , Femenino , Anciano , Persona de Mediana Edad , Masculino , Estudios Transversales , España , Telangiectasia Hemorrágica Hereditaria/epidemiología , Telangiectasia Hemorrágica Hereditaria/diagnóstico , Telangiectasia Hemorrágica Hereditaria/genética , Muerte , PrevalenciaRESUMEN
Fundamentos: La Telangiectasia Hemorrágica Hereditaria (THH) es una enfermedad de baja prevalencia, que se presenta con signos y síntomas muy heterogéneos y de la que apenas se dispone de estudios epidemiológicos de base poblacional. Los objetivos de este estudio fueron describir las características sociodemográficas de las personas afectadas por THH en la Comunitat Valenciana (CV), determinar su prevalencia y mortalidad, y analizar las fuentes de captación y pruebas de verificación utilizadas por el Sistema de Información de Enfermedades Raras de la CV (SIER-CV). Métodos: Se realizó un estudio epidemiológico observacional transversal de casos prevalentes de THH durante 2010-2019 en el SIER-CV. Se determinó la distribución de las características sociodemográficas y clínicas, la prevalencia y mortalidad, y se analizaron las fuentes de captación y pruebas de verificación utilizadas por SIER-CV. El análisis estadístico de los datos se realizó mediante el programa Stata (versión 16.1) y Microsoft Excel Office. Resultados: Durante 2010-2019 se identificaron doscientos casos, de los que el 55,5% eran mujeres. Las edades medias fueron: de captación 56,8 años, y de diagnóstico 50,9 años. El 48,4% fueron diagnosticados entre los treinta y seis, y los sesenta y cuatro años. Fallecieron el 25,5%, con 76,6 años de edad media, identificándose diferencias estadísticamente significativas en mayores de sesenta y cuatro años. La prevalencia fue 39,6 por cada millón de habitantes y la tasa cruda de mortalidad de 10,1 por cada millón de habitantes. El 95,5% se captaron por el Conjunto Mínimo Básico de Datos y la prueba de verificación más frecuente fue la base clínica (45,7%). Conclusiones: La tendencia ascendente de la prevalencia coincide con un mejor conocimiento de la THH, que facilita la detección de casos, y también con fallecimientos en edades avanzadas...(AU)
Background: The Hereditary Haemorrhagic Telangiectasia (HHT) is a low prevalence disease which presents heterogeneous signs and symptoms and just few population-based epidemiological studies are available. The aims of this paper were to describe the sociodemographic characteristics of people affected by HHT in the Valencian Region (VR), to determine its prevalence and mortality rate, and to analyse the sources of recruitment and verification tests used by the Rare Diseases Information System of the VR (SIER-CV).Methods: Cross-sectional observational epidemiological study of HHT prevalent cases between 2010-2019 in SIER-CV was performed. The distribution of sociodemographic and clinical characteristics were determined, the prevalence and mortality rates, and the sources of recruitment and verification tests used by SIER-CV were analysed. Statistical analysis was performed usingStata (version 16.1) and Microsoft Excel Office. Results: During 2010-2019, two hundred cases were identified, 55.5% were female. The mean ages were: 56.8 years at recruitment and 50.9 years at diagnosis. 48.4% of cases were diagnosed between thirty-six/sixty-four years of age. 25.5% died, with a mean age of 76.6 years, identifying statistically significant differences above the age of 64. The prevalence was 39.6/1,000,000 inhabitants and the crude mortality rate was 10.1/1,000,000 inhabitants. 95.5% of cases were recruited from the Hospital discharges database and the most frequent verification test was the clinical basis (45.7%). Conclusions: The increasing trend in prevalence coincides with a better knowledge of HHT, which favours its detection, and also with dying at older ages. To describe the situation of HHT in the VR facilitates its health management and contributes to the establishment of the relevant health policies for the HHT...(AU)
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Telangiectasia Hemorrágica Hereditaria , Prevalencia , Enfermedades Raras/epidemiología , Sistemas de Información , Ataxia Telangiectasia , España , Estudios Transversales , Estudios Epidemiológicos , Salud Pública , Enfermedades Raras/mortalidadRESUMEN
OBJECTIVE: To describe the impact of diagnosis delay in rare diseases and analyze psychosocial needs related to this delay in patients. METHOD: The qualitative approach has been used by conducting online group interviews with patients and family members in the Valencian Region (Spain) and a content analysis has been carried out. Two categories were differentiated: with diagnostic delay of 1 year or more and without diagnostic delay. Five interviews were conducted with a total of 25 participants. RESULTS: The content analysis showed unequal aspects vs. common aspects, in persons with or without diagnostic delay. People with delay expressed the need to feel supported in order to live with continuous uncertainty. People without delay verbalized the importance of adequate communication between patients and professionals. The problems by the COVID-19 were common in both groups; the participants expressed that they did not feel unattended in their disease by the health services. CONCLUSIONS: High resilience and coping capacity has been identified in people with rare disease, regardless of whether they have suffered diagnostic delay or not. The professional psychosocial support during the diagnostic process of these rare diseases is essential.
Asunto(s)
COVID-19 , Diagnóstico Tardío , Humanos , Enfermedades Raras/diagnóstico , COVID-19/diagnóstico , Adaptación Psicológica , Miedo , Investigación Cualitativa , Prueba de COVID-19RESUMEN
Objetivo: Describir el impacto de la demora diagnóstica de enfermedades raras y analizar las necesidades psicosociales de las personas afectadas en relación con dicha demora. Método: Se ha empleado el enfoque cualitativo mediante la realización de entrevistas grupales online a pacientes y familiares en la Comunitat Valenciana (España) y se ha efectuado un análisis de contenido. Se diferenciaron dos categorías: con demora diagnóstica de 1 año o más y sin demora diagnóstica. Se realizaron cinco entrevistas en las que participaron un total de 25 personas. Resultados: El análisis mostró aspectos desiguales frente a aspectos comunes, en personas con o sin demora diagnóstica. Las personas con demora manifestaron la necesidad de sentirse «sostenidas» para convivir con una incertidumbre continua. Las personas sin demora verbalizaron la importancia de una adecuada comunicación entre pacientes y profesionales. Los problemas surgidos por la COVID-19 fueron comunes en ambos grupos, y las personas participantes expresaron no sentirse desatendidas en su enfermedad por los servicios sanitarios durante la pandemia. Conclusiones: Se ha observado una gran capacidad de resiliencia y afrontamiento en las personas con enfermedades raras, independientemente de si han sufrido demora diagnóstica o no. El apoyo psicosocial profesionalizado durante el proceso de diagnóstico de estas enfermedades minoritarias es esencial. (AU)
Objective: To describe the impact of diagnosis delay in rare diseases and analyze psychosocial needs related to this delay in patients. Method: The qualitative approach has been used by conducting online group interviews with patients and family members in the Valencian Region (Spain) and a content analysis has been carried out. Two categories were differentiated: with diagnostic delay of 1 year or more and without diagnostic delay. Five interviews were conducted with a total of 25 participants. Results: The content analysis showed unequal aspects vs. common aspects, in persons with or without diagnostic delay. People with delay expressed the need to feel supported in order to live with continuous uncertainty. People without delay verbalized the importance of adequate communication between patients and professionals. The problems by the COVID-19 were common in both groups; the participants expressed that they did not feel unattended in their disease by the health services. Conclusions: High resilience and coping capacity has been identified in people with rare disease, regardless of whether they have suffered diagnostic delay or not. The professional psychosocial support during the diagnostic process of these rare diseases is essential. (AU)
Asunto(s)
Humanos , Pandemias , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/diagnóstico , Diagnóstico Tardío , España , Enfermedades Raras/diagnóstico , Investigación Cualitativa , Adaptación Psicológica , MiedoRESUMEN
Families with rare diseases (RDs) have unmet needs that are often overlooked by health professionals. Describing these needs and the impact of the disease could improve their medical care. A total of 163 surveys were obtained from patients visiting primary care centres in the Valencian Region (Spain), during 2015-2017, with a confirmed or suspected diagnosis of RD. Of the 84.7% with a confirmed diagnosis, 50.4% had a diagnostic delay exceeding one year, and it was more prevalent among adults (62.2%). Families with paediatric patients were in a worse economic situation, with lower incomes and higher monthly disease-related expenses (300 on average). These expenses were incurred by 66.5% of families and were mainly for medication (40.3%). Among them, 58.5% reported not being able to afford adjuvant therapies. The disease had an impact on 73.1% of families, especially on their routine and emotional state. Expenses, needs, and impacts were more frequent among families of patients with a history of hospitalisation or deterioration. Patients with delayed diagnosis had a higher consumption of drugs prior to diagnosis. People affected by RDs in the Valencian Region need therapies to improve their autonomy and emotional state. Health professionals should be aware of these needs.
Asunto(s)
Diagnóstico Tardío , Enfermedades Raras , Adulto , Niño , Estudios Transversales , Humanos , Enfermedades Raras/epidemiología , Enfermedades Raras/terapia , España/epidemiología , Encuestas y CuestionariosRESUMEN
Traditionally, epidemiological surveillance has focused on infectious diseases, but the concept of Public Health surveillance, introduced in Spain with the Law 33/2011, is broader and includes chronic diseases. Health strategies for these diseases need epidemiological information to improve understanding of socio-health needs and to facilitate the efficient management of resources. The European Union defines rare diseases (RD) as those that, being life-threatening or chronically debilitating, have a prevalence of less than 5 cases per 10,000 inhabitants. The RD Strategy of the National Health System, approved in 2009 and updated in 2014, recommends the development of regional registries of rare diseases (RAER), in addition to a national registry. The REpIER and Spain-RDR projects of the Institute of Health Carlos III (ISCIII) promoted the creation and regulation of 94% of the RAER. After more than 10 years of initiatives and work to improve the knowledge of RD's epidemiology in Spain, it was possible to implement the Spanish Registry of Rare Diseases (ReeR) in 2015, becoming one of the first population surveillance systems for chronic diseases of state scope. The ReeR procedures manual is the result of consensus between the RAER, the Ministry of Health, the ISCIII and the patient associations. The participatory methodology used for the implementation and launching of ReeR is considered an added value. The information system implemented will allow improving knowledge about the prevalence and distribution of RD in Spain.
Tradicionalmente la vigilancia epidemiológica se ha centrado en enfermedades transmisibles, pero el concepto de vigilancia en Salud Pública, incorporado en España con la Ley 33/2011, es más amplio e incluye las enfermedades crónicas. Las estrategias de salud para estas enfermedades necesitan disponer de información epidemiológica para mejorar el conocimiento de las necesidades sociosanitarias y facilitar la gestión eficiente de recursos. La Unión Europea define las enfermedades raras (ER) como aquellas que, con peligro de muerte o invalidez crónica, presentan una prevalencia inferior a 5 casos por cada 10.000 habitantes. La Estrategia en ER del Sistema Nacional de Salud, aprobada en 2009 y actualizada en 2014, recomienda desarrollar registros autonómicos de enfermedades raras (RAER) y uno estatal. Los proyectos REpIER y Spain-RDR del Instituto de Salud Carlos III (ISCIII) impulsaron la creación y regulación del 94% de los RAER; y tras más de 10 años de iniciativas y trabajos para mejorar el conocimiento de la epidemiología de las ER en España, se logró implementar el Registro Estatal de Enfermedades Raras (ReeR) en 2015, convirtiéndose en uno de los primeros sistemas de vigilancia poblacional de enfermedades crónicas de ámbito estatal. El manual de procedimientos del ReeR es el resultado del consenso entre los RAER, Ministerio de Sanidad, ISCIII y asociaciones de pacientes. La metodología participativa empleada para la implementación y puesta en funcionamiento del ReeR es considerada un valor añadido. El sistema de información implementado va a permitir mejorar el conocimiento sobre la prevalencia y distribución de las ER en España.
Asunto(s)
Enfermedades Raras , Consenso , Unión Europea , Humanos , Enfermedades Raras/epidemiología , Sistema de Registros , España/epidemiologíaRESUMEN
BACKGROUND: Rare diseases present a wide spectrum of clinical manifestations and severity levels and are often poorly known and underrepresented, making them difficult to classify. Diagnoses are usually coded using the International Classification of Diseases (ICD), with its different versions. In Spain, the ICD-10-ES (stem from the ICD-10-CM-Clinical Modification) is used throughout the National Healthcare System since 2016, indistinctively including rare diseases that often lack a specific code. Orphanet aims to provide high-quality resources on rare diseases. The goal was to interrelate the Orphanet classification with the ICD-10-ES in order to engage a tool to track rare diseases diagnosis and characterize the improvement space for the identification of rare diseases patients in the Spanish Healthcare System. METHODS: 5775 disorder level ORPHAcodes were mapped to ICD-10-ES codes by comparing the descriptors associated in both classifications. ORPHAcodes were then clustered based on their assigned ICD-10-ES chapter and the redundancy of each individual ICD-10-ES code was calculated by counting the ORPHAcodes they mapped to. Three groups were established: Group 1 (1 ORPHAcode per ICD-10-ES), Group 2 (between 2-49 ORPHAcodes per ICD-10-ES) and Group 3 (≥ 50 ORPHAcodes per ICD-10-ES). RESULTS: Equivalences to 1700 ICD-10-ES codes were established for 5664 ORPHAcodes. The ORPHAcodes distribution within the ICD-10-ES showed an aggregation in the "Q" (> 40%), "G" (> 14%), and "E" (12%) chapters. The availability of ICD-10-ES codes to map ORPHAcodes reached its lowest at the "G" and "Q" chapters with less than 0.2 ICD-10-ES codes available per ORPHAcode. Global ICD-10-ES codes redundancy analysis revealed that only 1055 of the equivalences pertain to group 1. Group 2 contained 3358 equivalences with 634 ICD-10-ES codes while 1322 equivalences were group 3 (11 ICD-10-ES). Within ICD-10-ES chapters, "G" and "Q" contained over 30% and 45% of their own equivalences in the highest redundancy level (group 3) respectively, but under 10% one to one equivalences each (group 1). CONCLUSIONS: ICD-10-ES codes have not enough specificity to identify rare diseases. Direct mapping between ICD and ORPHAcodes or the integration of ORPHAcodes at the healthcare system for diagnoses codification would enable better detection and epidemiological analysis of rare diseases.
Asunto(s)
Clasificación Internacional de Enfermedades , Enfermedades Raras , Atención a la Salud , Humanos , Motivación , Enfermedades Raras/diagnóstico , EspañaRESUMEN
OBJECTIVE: Tetralogy of Fallot is characterized by the presence of four congenital heart defects. Objective: to describe the temporal trend and distribution of Tetralogy of Fallot, in children under one year in the Valencian Region. METHODS: Cases with Tetralogy of Fallot (code Q21.3 from the ICD10-British Paediatric Association) were selected from the Congenital Anomalies Population-based Registry between 2007-2017. Prevalence per 10,000 births with 95%CI was calculated, and a descriptive analysis of sociodemographic and clinical variables was made. RESULTS: 165 cases were identified (43.6% male, 30.9% female and 25.5% unknown). The overall prevalence was 3.1/10,000 births (95%CI:2.6-3.6), being 2015 and 2017 the years with the highest (4.3/10,000 births and 4.7/10,000 births respectively) and 2011 with the lowest (1.8/10,000 births). 72.1% were live births, 24.8% Termination of Pregnancy for Fetal Anomaly (TOPFA) and 3.0% stillbirths. The prevalence in live births was 2.2/10,000 births (95%CI:1.8-2.7) and in TOPFA it was 0.8/10,000 births (95%CI:0.5-1.0), identifying an increasing trend along the period in the last one. 10.1% of live births died during the first year of life and 55.8% were diagnosed prenatally. Mothers younger than 20 years had the highest prevalence (4.8/10,000 births). CONCLUSIONS: The prevalence obtained in the Valencian Region was slightly lower than EUROCAT's but coincides with that of the registries that are closer geographically, and in all of them it is noted that their increasing trend specifically affects cases ending in TOPFA.
OBJETIVO: La Tetralogía de Fallot está caracterizada por la presencia de cuatro anomalías congénitas cardíacas. El objetivo de este trabajo fue describir la tendencia temporal y distribución de la Tetralogía de Fallot en menores de un año en la Comunitat Valenciana. METODOS: Se seleccionaron los casos con Tetralogía de Fallot (código Q21.3 de la CIE10 de la Asociación Pediátrica Británica) nacidos entre 2007-2017 del Registro Poblacional de anomalías congénitas de la Comunitat Valenciana. Se calculó la prevalencia por 10.000 nacimientos con IC95% y se realizó un análisis descriptivo de las variables sociodemográficas y clínicas. RESULTADOS: Se identificaron 165 casos (43,6% niños, 30,9% niñas y 25,5% de sexo desconocido). La prevalencia global fue 3,1/10.000 nacimientos (IC95%:2,63,6), siendo los años de mayor prevalencia 2015 y 2017 (4,3/10.000 nacimientos y 4,7/10.000 nacimientos respectivamente) y 2011 el de menor (1,8/10.000 nacimientos). El 72,1% fueron nacidos vivos, el 24,8% Interrupciones Voluntarias del Embarazo y el 3,0% nacidos muertos. La prevalencia en nacidos vivos fue 2,2/10.000 nacimientos (IC95%:1,8-2,7) y en Interrupciones Voluntarias del Embarazo fue 0,8/10.000 nacimientos (IC95%:0,5-1,0), identificándose en la segunda una tendencia en aumento a lo largo del periodo. El 10,1% de nacidos vivos fallecieron durante el primer año de vida y el 55,8% se diagnosticaron prenatalmente. El grupo con mayor prevalencia fueron las embarazadas menores de 20 años (4,8/10.000 nacimientos. CONCLUSIONES: La prevalencia obtenida en la Comunitat Valenciana fue ligeramente inferior a la de EUROCAT pero coincide con la de registros próximos geográficamente, y en todos ellos destaca que su tendencia creciente afecta específicamente a casos que finalizan en Interrupciones Voluntarias del Embarazo.
Asunto(s)
Monitoreo Epidemiológico , Cardiopatías Congénitas/epidemiología , Tetralogía de Fallot/epidemiología , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Prevalencia , Sistema de Registros , España/epidemiologíaRESUMEN
OBJECTIVE: To evaluate the sources of information used by the Regional Population-based Registries of Rare Diseases (RRD) for Wilson's Disease identification in Spain; to calculate its prevalence and mortality; and to describe the sociodemographic characteristics of those affected. METHOD: Cross-sectional epidemiological study, period 2010-2015. Possible cases were identified by codes 275.1 (ICD-9-CM), E83.0 (ICD-10) and 905 (ORPHAcode) in: 15 participating RRD and the Rare Disease Patients Registry of the Carlos III Health Institute. The diagnoses were confirmed through a clinical documentation review. The positive predictive value (PPV) of the sources of information used by RRD and their combinations were obtained. The prevalence, mortality and the distribution of sociodemographic characteristics were calculated. RESULTS: The Hospital Discharge Database (HDD) was the most used source by the RRD (PPV=39.4%), followed by the Orphan Drugs Registry (ODR) (PPV=81.9%). The Clinical History of Primary Care (PC) obtains PPV=55.9%. The combinations with highest PPV were the ODR with HDD (PPV=95.8%) and the ODR with PC (PPV=92.9%). 514 cases were confirmed, 57.2% men, with a median age of diagnosis of 21.3 years. The prevalence was 1.64/100,000 inhabitants in 2015 and mortality rate was 3.0%, being both higher in men. CONCLUSIONS: Incorporation of ODR and PC into the RRD is recommended, as its combination and ODR with HDD could be used as an automatic validation criterion for Wilson's disease. The prevalence obtained was similar to that of countries close to Spain.
Asunto(s)
Degeneración Hepatolenticular , Enfermedades Raras , Adulto , Estudios Transversales , Femenino , Degeneración Hepatolenticular/epidemiología , Humanos , Masculino , Enfermedades Raras/epidemiología , Sistema de Registros , España/epidemiología , Adulto JovenRESUMEN
OBJECTIVE: Osteogenesis imperfecta (OI) is a rare connective tissue and bone disease that results in a bone fragility of varying severity. The objective was to determine and describe the OI in the Valencia Region (VR) during the period 2004 to 2014. METHODS: From the Rare Diseases Information System of the VR (SIER-CV) patients from 2004 to 2014 with the codes of the International Classification of Diseases for the OI were identified: 756.51 from the 9th Revision-Clinical Modification and Q78.0 from the 10th Revision. The information was validated by reviewing clinical documentation (mainly electronic health records) and a descriptive analysis of the confirmed cases (diagnosis of OI in the clinical documentation) was performed. RESULTS: 162 patients were identified with a code for OI. 145 of the 161 patients with available clinical documentation were confirmed as cases. The prevalence was 0.29 per 10.000 inhabitants. 93.1% were Spanish, 54.5% were women and they were treated in 25 different hospitals in the VR. The type of OI was known in the 26.4% of the cases and type I was the most common (9.7%). 6.2% of the patients died with an average death age of 60.8 years. 44.8% of patients received treatment with bisphosphonates and 10.4% had affected relatives. CONCLUSIONS: The real situation of the OI in the VR has been established, which will allow a better planning in the health actions to improve the quality of life of the affected ones and their families.
OBJETIVO: La Osteogénesis Imperfecta (OI) es una enfermedad rara del tejido conectivo y óseo que resulta en una fragilidad ósea de diversa severidad. El objetivo fue determinar y describir la situación de la OI en la Comunitat Valenciana (CV) durante el periodo 2004-2014. METODOS: A partir del Sistema de Información de Enfermedades Raras de la CV (SIER-CV) se identificaron los pacientes con los códigos de la Clasificación Internacional de Enfermedades pertenecientes a la OI: el 756.51 de la 9ª y/o el Q78.0 de la 10ª revisión, durante el período 2004-2014. Se validaron los datos mediante la revisión de documentación clínica (historia clínica electrónica principalmente) y de los casos confirmados (diagnóstico de OI presente en la documentación clínica) se elaboró un análisis descriptivo. RESULTADOS: Se identificaron 162 pacientes con código de OI. Se confirmaron 145 casos de los 161 con la documentación clínica accesible. La prevalencia fue de 0,29 por 10.000 habitantes. El 93,1% eran españoles, el 54,5% mujeres y fueron atendidos en 25 hospitales diferentes de la CV. Se identificó el tipo de OI en el 24,8% de los casos, siendo el tipo I el más habitual (9,7%). Fallecieron el 6,2% con una edad media al fallecimiento de 60,8 años. El 44,8% de pacientes recibió tratamiento con bifosfonatos y el 10,4% tenían familiares afectados. CONCLUSIONES: Se ha establecido la situación real de la OI en la CV, lo que permitirá una mejor planificación en las acciones sanitarias para mejorar la calidad de vida de los afectados y sus familiares.
Asunto(s)
Osteogénesis Imperfecta/epidemiología , Adulto , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Osteogénesis Imperfecta/complicaciones , Osteogénesis Imperfecta/diagnóstico , Osteogénesis Imperfecta/terapia , Prevalencia , Enfermedades Raras/complicaciones , Enfermedades Raras/diagnóstico , Enfermedades Raras/epidemiología , Enfermedades Raras/terapia , España/epidemiologíaRESUMEN
Objetivo: Estimar la prevalencia de pacientes con terapia anticoagulante oral (TAO) en la Comunitat Valenciana (CV) y evaluar la calidad del seguimiento de la TAO con antagonistas de la vitaminaK (AVK) realizado en atención primaria. Diseño: Estudio observacional transversal realizado a través de la Red Centinela Sanitaria de la Comunitat Valenciana (RCSCV), que incluye una encuesta y el análisis retrospectivo del control de la TAO. Emplazamiento: Atención primaria (AP), Comunitat Valenciana (CV), España. Participantes: Todos los pacientes con ≥18años con TAO que consultaron durante el año 2014. La población cubierta por los 59 médicos de la RCSCV supone un 2,2% de la población adulta de la CV, y es representativa de esta. Mediciones principales: Datos demográficos, socioeconómicos, de salud y referentes a la TAO. La calidad del seguimiento de la TAO con AVK fue valorada mediante el porcentaje de tiempo dentro de rango terapéutico (TRT), calculado mediante el método Rosendaal. Resultados: Se registraron 1.144 pacientes (edad media 74,5±11años; 49,7% mujeres). La prevalencia de TAO en la CV es de 1,3 casos por 100 habitantes. El perfil característico de estos pacientes es una persona añosa, pluripatológica, con bajo nivel educativo, que vive acompañada. La fibrilación auricular es la indicación más habitual. El 82,8% de los pacientes con TAO con AVK llevaron seguimiento a través de AP. El TRT medio fue del 65,0%, y el 53,9% de pacientes presentaron un TRT ≥65%. El 74,4% de los pacientes con un control inadecuado fueron percibidos como bien controlados por el médico de AP. Conclusiones: La prevalencia de la TAO es alta y se prevé que siga aumentando. El grado de control alcanzado cumple con el estándar de calidad generalmente aceptado (TRT medio ≥ 65%) y es comparable al observado en otros estudios nacionales e internacionales. Sin embargo, hay un amplio margen de mejora. Es crucial optimizar la gestión de esta terapia de la manera más eficaz y coste-efectiva posible. Entre otras medidas, se debe mejorar el acceso de los facultativos a la información clínica de sus pacientes (AU)
Objective: To estimate the prevalence of patients with oral anticoagulant therapy (OAT) in the Region of Valencia and to evaluate the quality of management of OAT with vitamin K antagonists (VKA) carried out in primary healthcare. Design: Observational cross-sectional study conducted through the Health Sentinel Network of the Region of Valencia, which includes a survey and the retrospective analysis of OAT monitoring. Setting: Primary healthcare, Region of Valencia, Spain. Subjects: All patients aged 18years or older on OAT who consulted during the year 2014. The population covered by the 59 doctors of the Health Sentinel Network constitutes 2.2% of the adult population of the Region of Valencia, and it is representative of it. Key measurements Demographic, socioeconomic and health data as well as information concerning OAT. Quality of OAT management with VKA was assessed by means of the percentage of time in therapeutic range (TTR), computed using the Rosendaal method. Results: A total of 1,144 patients were recorded (mean age 74.5±11 years; 49.7% women). Prevalence of OAT in the Region of Valencia is 1.3 cases per 100 population. The characteristic profile of these patients is an old person, with several comorbidities and a low level of education, who lives accompanied. Atrial fibrillation is the most common indication. 82.8% of patients on OAT with VKA were monitored in primary healthcare. The average TTR was 65.0%, and 53.9% of patients had a TTR ≥ 65%. Among inadequately controlled patients, 74.4% were perceived as well-controlled by their primary care doctor. Conclusions. Prevalence of OAT is high, and it is expected to increase. The degree of control achieved meets the generally accepted quality standard (mean TTR ≥ 65%), and it is comparable to that observed in other national and international studies. However, there is wide scope for improvement. It is crucial to optimize the management of this therapy in the most effective and cost-effective way. Among other measures, access of physicians to their patients clinical information should be improved (AU)
Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Anticoagulantes/uso terapéutico , Trastornos de la Coagulación Sanguínea/tratamiento farmacológico , Administración del Tratamiento Farmacológico/organización & administración , Estudios Transversales , Calidad de la Atención de Salud/tendencias , Vigilancia de Guardia , Atención Primaria de Salud/organización & administración , Prescripción Electrónica/estadística & datos numéricosRESUMEN
OBJECTIVE: To estimate the prevalence of patients with oral anticoagulant therapy (OAT) in the Region of Valencia and to evaluate the quality of management of OAT with vitaminK antagonists (VKA) carried out in primary healthcare. DESIGN: Observational cross-sectional study conducted through the Health Sentinel Network of the Region of Valencia, which includes a survey and the retrospective analysis of OAT monitoring. SETTING: Primary healthcare, Region of Valencia, Spain. SUBJECTS: All patients aged 18years or older on OAT who consulted during the year 2014. The population covered by the 59 doctors of the Health Sentinel Network constitutes 2.2% of the adult population of the Region of Valencia, and it is representative of it. KEY MEASUREMENTS: Demographic, socioeconomic and health data as well as information concerning OAT. Quality of OAT management with VKA was assessed by means of the percentage of time in therapeutic range (TTR), computed using the Rosendaal method. RESULTS: A total of 1,144 patients were recorded (mean age 74.5±11 years; 49.7% women). Prevalence of OAT in the Region of Valencia is 1.3 cases per 100 population. The characteristic profile of these patients is an old person, with several comorbidities and a low level of education, who lives accompanied. Atrial fibrillation is the most common indication. 82.8% of patients on OAT with VKA were monitored in primary healthcare. The average TTR was 65.0%, and 53.9% of patients had a TTR ≥65%. Among inadequately controlled patients, 74.4% were perceived as well-controlled by their primary care doctor. CONCLUSIONS: Prevalence of OAT is high, and it is expected to increase. The degree of control achieved meets the generally accepted quality standard (mean TTR ≥65%), and it is comparable to that observed in other national and international studies. However, there is wide scope for improvement. It is crucial to optimize the management of this therapy in the most effective and cost-effective way. Among other measures, access of physicians to their patients' clinical information should be improved.
Asunto(s)
Anticoagulantes/uso terapéutico , Monitoreo de Drogas/normas , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Vigilancia de la Población , Atención Primaria de Salud , España , Adulto JovenRESUMEN
Fundamentos: La Osteogénesis Imperfecta (OI) es una enfermedad rara del tejido conectivo y óseo que resulta en una fragilidad ósea de diversa severidad. El objetivo fue determinar y describir la situación de la OI en la Comunitat Valenciana (CV) durante el periodo 2004-2014. Métodos: A partir del Sistema de Información de Enfermedades Raras de la CV (SIER-CV) se identificaron los pacientes con los códigos de la Clasificación Internacional de Enfermedades pertenecientes a la OI: el 756.51 de la 9ª y/o el Q78.0 de la 10ª revisión, durante el período 2004-2014. Se validaron los datos mediante la revisión de documentación clínica (historia clínica electrónica principalmente) y de los casos confirmados (diagnóstico de OI presente en la documentación clínica) se elaboró un análisis descriptivo. Resultados: Se identificaron 162 pacientes con código de OI. Se confirmaron 145 casos de los 161 con la documentación clínica accesible. La prevalencia fue de 0,29 por 10.000 habitantes. El 93,1% eran españoles, el 54,5% mujeres y fueron atendidos en 25 hospitales diferentes de la CV. Se identificó el tipo de OI en el 24,8% de los casos, siendo el tipo I el más habitual (9,7%). Fallecieron el 6,2% con una edad media al fallecimiento de 60,8 años. El 44,8% de pacientes recibió tratamiento con bifosfonatos y el 10,4% tenían familiares afectados. Conclusión: Se ha establecido la situación real de la OI en la CV, lo que permitirá una mejor planificación en las acciones sanitarias para mejorar la calidad de vida de los afectados y sus familiares (AU)
Background: Osteogenesis imperfecta (OI) is a rare connective tissue and bone disease that results in a bone fragility of varying severity. The objective was to determine and describe the OI in the Valencia Region (VR) during the period 2004 to 2014. Methods: From the Rare Diseases Information System of the VR (SIER-CV) patients from 2004 to 2014 with the codes of the International Classification of Diseases for the OI were identified: 756.51 from the 9th Revision-Clinical Modification and Q78.0 from the 10th Revision. The information was validated by reviewing clinical documentation (mainly electronic health records) and a descriptive analysis of the confirmed cases (diagnosis of OI in the clinical documentation) was performed. Results: 162 patients were identified with a code for OI. 145 of the 161 patients with available clinical documentation were confirmed as cases. The prevalence was 0.29 per 10.000 inhabitants. 93.1% were Spanish, 54.5% were women and they were treated in 25 different hospitals in the VR. The type of OI was known in the 26.4% of the cases and type I was the most common (9.7%). 6.2% of the patients died with an average death age of 60.8 years. 44.8% of patients received treatment with bisphosphonates and 10.4% had affected relatives. Conclusion: The real situation of the OI in the VR has been established, which will allow a better planning in the health actions to improve the quality of life of the affected ones and their families (AU)